Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of “Moderate Buy” from Analysts

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective […]

Leave a Reply

Your email address will not be published.

Previous post Ukraine October 2023: Volkswagen, BMW surge, Zeekr lands inside Top 30
Next post Insider Selling: Oracle Co. (NYSE:ORCL) Director Sells $260,330.25 in Stock